Bcr-Abl

Inhibitory Selectivity

Catalog No.	Inhibitor Name	Bcr-Abl	Abl	Other
A10290	Dasatinib	****	****	Src,c-Kit (D816V),c-Kit (wt)
A10468	Imatinib Mesylate		*	c-Kit,PDGFR
A10108	Saracatinib		**	c-Src,LCK,EGFR (L861Q)
A10080	Ponatinib	****	****	PDGFRα,VEGFR2,FGFR1
A10644	Nilotinib	**
A10715	Danusertib	**	**	Aurora A,TrkA,RET
A10095	AT9283		***	JAK3,JAK2,Aurora B
A10988	Degrasyn	*		DUB
A10119	Bafetinib	***	***	Lyn
A10508	KW-2449	**	***	FLT3 (D835Y),FLT3,FGFR1
A10661	NVP-BHG712		*	EphB4,C-Raf,c-Src
A11200	Rebastinib		***	FLT3,KDR,Tie-2
A15849	GZD824 Dimesylate	****	****
A11439	GNF-2	*
A15887	GNF-7	***	*
A13029	Radotinib	**
A16320	Dasatinib Monohydrate	****	****	Src,c-Kit (D816V),c-Kit (wt)
A13237	GNF-5	*
A13120	PD173955	***		Src
A11379	DPH
A13530	Flumatinib mesylate		****	PDGFRβ, c-Kit

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Quick View
Imatinib (Gleevec)

Catalog No. A10259
Quick View

添加到收藏
PDGFR 抑制剂

Imatinib (Gleevec)是一种多靶点酪氨酸激酶抑制剂，抑制v-Abl、c-Kit和PDGFR的IC50分别为0.6，0.1和0.1 μM。了解更多

Product Citations (6)

Bulk Inquiry Free Sample
- Aya Hasan Alshammari, .et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition, Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
- Takafumi Shima, .et al. Glucose transporter-1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells, Oncol Rep, 2022, 47: 7 PMID: 34738628
- Reiko Watanabe, .et al. Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration, J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
- BM Duggan, .et al. RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice, Endocrinology, 2020, May 30;bqaa086 PMID: 32473019
- Li Li, .et al. Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1, Leukemia Res, 2019, 78:12-20 PMID: 30660961
- Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277